https://www.thebodypro.com/category/prep-hiv-pre-exposure-prophylasxis/tag/news

The Latest

green light

U.S. Waits on Approval of Long-Acting HIV Treatment Cabotegravir and Rilpivirine as European Union Gives the Green Light

The era of once-a-month HIV treatment has begun in the European Union—and it may soon commence in the U.S. as well. Long-acting pre-exposure prophylaxis (PrEP) is also on the horizon.

By Michael Broder
teamwork

This Week in HIV Research: Teamwork Makes the Dream Work

Dec. 28, 2020: The power of clinic-pharmacy collaborations; overcoming COVID-19-induced barriers to HIV care; urine testing as a PrEP adherence tool; using incarceration history in PrEP Rx assessments.

By Barbara Jungwirth and Myles Helfand
Promo Image

This Week in HIV Research: Our Immensely Intersectional Epidemic

Dec. 3, 2020: A simple scoring system for PrEP referral; integrating meth use and HIV prevention interventions; genetically linked HIV strains cross county lines; viral suppression rates in first vs. second pregnancies.

By Barbara Jungwirth and Myles Helfand
intramuscular injection

HIV PrEP Is Finally About to Get Its Shot

PrEP for HIV is a pill. It has always been a pill. But it will not always be a pill, thanks to two major trials evaluating cabotegravir, an integrase inhibitor formulated for intramuscular injection, as PrEP.

By David Alain Wohl, M.D.
prescription bottle

PrEP and Prior Authorization: A Discriminatory Cheap Ploy

An important new analysis describes a key barrier to PrEP in the U.S., one that is almost sinister in its application predominantly in southern states.

By David Alain Wohl, M.D.
chlamydia

DoxyPEP for STIs: Are We Ready for Prophylactic Doxycycline for MSM on HIV PrEP?

A recent expert debate explored the pros and cons of prescribing the antibiotic as a preventive measure for a subset of people at especially high risk for sexually transmitted infections.

By Michael Broder
doctor talking to unrecognizable patient

For PrEP to Work, Shared Doctor-Patient Decision-Making Is Key

The process of choosing between PrEP options is often not straightforward. Oni Blackstock, M.D., explains how providers can help ensure their patients end up with the most successful option for them.

By Terri Wilder, M.S.W.
Latinx patient

‘PrEP for Women Too’ Campaign Aims to Bring This Empowering HIV Prevention Tool to More Black and Latinx Women

Despite PrEP being safe to take for people of all genders, there’s still a lag in uptake among cisgender women.

By Juan Michael Porter II
sizes and shapes

This Week in HIV Research: Many Sizes Fit Many People

Oct. 15, 2020: Adherence barriers among Latinx MSM; Atlanta's Ending the HIV Epidemic priorities; Ryan White HIV service coordination; PrEP, white coat dosing, and drug resistance.

By Barbara Jungwirth and Myles Helfand
MSM

This Week in HIV Research: Incidence and Clinical Care Trends Among MSM

Oct. 1, 2020: HIV surveillance trends among U.S. MSM; health insurance and viral suppression; PrEP prescribing among motivated clinicians; PrEP sharing between MSM.

By Barbara Jungwirth and Myles Helfand